Rogan, RFK Jr & the Peptide Reboot: Hype vs the Rulebook

Affiliate Disclosure: This newsletter contains affiliate links. When you purchase through these links using code PROBIO15, I may earn a commission at no additional cost to you. I only recommend vendors I personally use and trust.

What RFK Jr actually said (and didn’t)

On Rogan, RFK Jr (now Health and Human Services Secretary) said the FDA will “soon act” to move roughly 14 peptides off the restricted list and make them available again through compounding pharmacies. He framed this as reversing an earlier decision that pulled a group of popular therapeutic peptides out of 503A/503B pharmacies and pushed them into the shadows.

Two critical clarifications:

• First, there is no official FDA rule or guidance yet that names the 14 peptides or formally moves them back to Category 1.
  

• Second, even if they move, Category 1 is not the same thing as “FDA‑approved drug” – it simply means a licensed compounding pharmacy can legally use that peptide as a bulk drug substance when there’s a valid prescription.
  

So this is a policy intention broadcast on a podcast, not a finished regulation. The governing framework for peptides is unchanged as of today.

The roster: who’s likely in the 14?

Back in 2023–2024, the FDA dropped 19 widely used peptides into Category 2, effectively banning traditional compounding of things like BPC‑157, Thymosin Alpha‑1, TB‑500 analogs, and several nootropic and metabolic peptides. RFK Jr’s “about 14” comment implies most of that list may come back, with a smaller subset staying restricted.

We don’t have an official list, but across clinician and legal write‑ups, the same familiar names keep showing up as “likely to be restored”:

• BPC‑157 – soft tissue, ligament and tendon recovery, gut claims
  

• TB‑500 / Thymosin Beta‑4 fragment – tissue repair and angiogenesis support
  

• Thymosin Alpha‑1 – immune modulation and adjuvant support
  

• AOD‑9604 – fat‑loss/weight‑management adjunct
  

• GHK‑Cu (injectable) – skin, hair, wound‑healing support
  

• CJC‑1295 and/or Ipamorelin – GH axis, body composition, recovery
  

• Semax and Selank – cognitive and anxiolytic support
  

• MOTS‑C – mitochondrial and metabolic signaling
  

• KPV, Kisspeptin‑10, DSIP and related regulatory peptides
  

On the flip side, a handful of peptides are consistently flagged as likely to stay in Category 2: Melanotan II (oncology and cardiovascular concerns), LL‑37 (limited human data), GHRP‑2 (prolactin/cortisol issues), PEG‑MGF, and possibly one or two of the more aggressive GH secretagogues.

Again: these are informed guesses from analysts reading tea leaves, not an official FDA table.

Why this matters: the gray‑market detox

When the FDA moved these 19 peptides into Category 2, they didn’t make demand disappear, they just pushed it into the gray market: “for research only” sites, overseas injectables, and misbranded products sold directly to consumers. For a lot of people, that meant:

• No clinician oversight
  

• No guaranteed sterility or potency
  

• COAs that may or may not match what’s in the vial
  

Mainstream outlets are only now catching up to the size of this problem, with coverage of influencer‑driven peptide use and reports of mislabeling, contamination, and adverse events related to unregulated products. If the FDA really does reclassify most of these back to Category 1, the biggest win won’t be “you can finally get BPC‑157 again” – it’s that you might be able to get it from a U.S. pharmacy with quality controls, instead of a random lab in another time zone.

So what should you do with your stack right now?

Here’s the part most headlines skip: nothing about your legal or safety landscape has changed yet. Category 2 peptides are still Category 2 until the FDA says otherwise. That means:

• Gray‑market peptides are still the same risk profile this week as they were last week.
  

• Compounding pharmacies still cannot legally prepare these as bulk substances until the rulemaking is finalized.
  

If you’re already experimenting in the gray zone, this is the time to tighten your sourcing: demand real COAs, ask about sterility testing, verify batch numbers, and be honest with your clinician about what you’re using. If you’ve been waiting on the sidelines for more legitimate access, your move now is to watch for:

• FDA updates to the bulk drug substances list
  

• Announcements from reputable compounding pharmacies and peptide‑literate clinicians once they are actually allowed to source and prescribe again
  

I’ll be tracking this story as it evolves and building a living status board for each of the 19 peptides: proposed status, final FDA category, and what that means for real‑world access. If there’s a specific peptide you want to see at the top of that board – BPC‑157, TB‑500, Semax/Selank, MOTS‑C.

Modern life is inflammatory.

Chronic stress. Environmental toxins. Low-grade inflammation that quietly chips away at energy, focus, and long-term health.

BrocElite Plus delivers stabilized sulforaphane, one of the most researched plant compounds for cellular defense, detox support, and neuroprotection.

Sulforaphane activates your body’s internal antioxidant systems. It supports inflammation control. It strengthens detox pathways at the cellular level.

Coaching Packages Updated

Project Biohacking Resources

Some links may be affiliate links; I may earn a small commission at no extra cost to you. I only recommend vendors I use and trust, Biolongevity Labs!

Quick links to Vetted Sources & Discount Codes

👇🏻15% - 20% off Peptide Sites Using PROBIO15 Coupon Code 👇🏻

Biolongevity Labs | Limitless Biotech | Rejuvatide Peptides | CanLabs Intl  

Ascension Peptides | Peptidology

👇🏻Supplements Affiliates👇🏻

👇🏻Lab Affiliatess👇🏻

 Guides

From Around The Web

🔚 Outro & Final Thoughts

This isn’t a reopening. It’s a signal.

For the first time since the 2023 crackdown, there’s credible momentum toward pulling parts of the peptide market back into a regulated, clinical framework. That matters. But until the FDA publishes actual changes to the bulk substances list, nothing about the rules has changed.

The real takeaway is not “peptides are back.” It’s that the path back is being discussed at the highest level, and that shifts how you should think about risk, sourcing, and timing.

If you are already in this space, tighten your standards. If you have been waiting for legitimate access, stay patient and watch the rulemaking, not the headlines.

This story will not be decided on a podcast. It will be decided in FDA updates, pharmacy announcements, and how the final categories are written.

That is where the real signal will show up.

Until next time, stay ahead of your age!
– Jeff
Founder, Project Biohacking